These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36213666)

  • 1. Outcome-based reimbursement in Central-Eastern Europe and Middle-East.
    Ádám I; Callenbach M; Németh B; Vreman RA; Tollin C; Pontén J; Dawoud D; Elvidge J; Crabb N; van Waalwijk van Doorn-Khosrovani SB; Pisters-van Roy A; Vincziczki Á; Almomani E; Vajagic M; Oner ZG; Matni M; Fürst J; Kahveci R; Goettsch WG; Kaló Z
    Front Med (Lausanne); 2022; 9():940886. PubMed ID: 36213666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed payment schemes in Central-Eastern Europe and Middle-East.
    Ádám I; Callenbach M; Németh B; Vreman RA; Pontén J; Strbad T; Dawoud D; Kostyuk A; Seyam A; Nagy L; Goettsch WG; Kaló Z
    Front Med (Lausanne); 2022; 9():940371. PubMed ID: 36035424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reimbursement and payment models in Central and Eastern European as well as Middle Eastern countries: A survey of their current use and future outlook.
    Callenbach MHE; Ádám L; Vreman RA; Németh B; Kaló Z; Goettsch WG
    Drug Discov Today; 2023 Jan; 28(1):103433. PubMed ID: 36372328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for patient involvement in health technology assessment in Central and Eastern European countries.
    Jakab I; Dimitrova M; Houÿez F; Bereczky T; Fövényes M; Maravic Z; Belina I; Andriciuc C; Tóth K; Piniazhko O; Hren R; Gutierrez-Ibarluzea I; Czech M; Tesar T; Niewada M; Lorenzovici L; Kamusheva M; Manova M; Savova A; Mitkova Z; Tachkov K; Németh B; Petykó ZI; Dawoud D; Delnoij D; Knies S; Goettsch W; Kaló Z
    Front Public Health; 2023; 11():1176200. PubMed ID: 37465169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review.
    Kawalec P; Tesar T; Vostalova L; Draganic P; Manova M; Savova A; Petrova G; Rugaja Z; Männik A; Sowada C; Stawowczyk E; Harsanyi A; Inotai A; Turcu-Stiolica A; Gulbinovič J; Pilc A
    Front Pharmacol; 2017; 8():892. PubMed ID: 29326583
    [No Abstract]   [Full Text] [Related]  

  • 7. Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel.
    Facey KM; Espin J; Kent E; Link A; Nicod E; O'Leary A; Xoxi E; van de Vijver I; Zaremba A; Benisheva T; Vagoras A; Upadhyaya S
    Pharmacoeconomics; 2021 Sep; 39(9):1021-1044. PubMed ID: 34231135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Illustrating the Financial Consequences of Outcome-Based Payment Models From a Payers Perspective: The Case of Autologous Gene Therapy Atidarsagene Autotemcel (Libmeldy®).
    Callenbach MHE; Schoenmakers D; Vreman RA; Vijgen S; Timmers L; Hollak CEM; Mantel-Teeuwisse AK; Goettsch WG
    Value Health; 2024 Aug; 27(8):1046-1057. PubMed ID: 38795960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis.
    Vreman RA; Broekhoff TF; Leufkens HG; Mantel-Teeuwisse AK; Goettsch WG
    Int J Environ Res Public Health; 2020 Nov; 17(22):. PubMed ID: 33182732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries.
    Kovács S; Kaló Z; Daubner-Bendes R; Kolasa K; Hren R; Tesar T; Reckers-Droog V; Brouwer W; Federici C; Drummond M; Zemplényi AT
    Health Econ; 2022 Sep; 31 Suppl 1(Suppl 1):195-206. PubMed ID: 35322478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managed Entry Agreements for Pharmaceutical Products in Middle East and North African Countries: Payer and Manufacturer Experience and Outlook.
    Maskineh C; Nasser SC
    Value Health Reg Issues; 2018 Sep; 16():33-38. PubMed ID: 29936067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges.
    Daubner-Bendes R; Kovács S; Niewada M; Huic M; Drummond M; Ciani O; Blankart CR; Mandrik O; Torbica A; Yfantopoulos J; Petrova G; Holownia-Voloskova M; Taylor RS; Al M; Piniazhko O; Lorenzovici L; Tarricone R; Zemplényi A; Kaló Z
    Front Public Health; 2020; 8():612410. PubMed ID: 33490024
    [No Abstract]   [Full Text] [Related]  

  • 13. Values, challenges, and responses associated with high-priced potential cures: perspectives of diverse stakeholders in South Korea.
    Hong J; Bae EY; Lee HJ; Lee TJ; Clarke P
    Cost Eff Resour Alloc; 2024 Mar; 22(1):20. PubMed ID: 38439068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
    Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
    Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
    Zelei T; Molnár MJ; Szegedi M; Kaló Z
    Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managed Entry Agreements: Policy Analysis From the European Perspective.
    Dabbous M; Chachoua L; Caban A; Toumi M
    Value Health; 2020 Apr; 23(4):425-433. PubMed ID: 32327159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerating patient access to oncology medicines with multiple indications in Europe.
    Lawlor R; Wilsdon T; Darquennes E; Hemelsoet D; Huismans J; Normand R; Roediger A
    J Mark Access Health Policy; 2021; 9(1):1964791. PubMed ID: 34436506
    [No Abstract]   [Full Text] [Related]  

  • 19. The use of non-economic criteria in pricing and reimbursement decisions in Central and Eastern Europe: issues, trends and recommendations.
    Kolasa K; Kalo Z; Zah V
    Expert Rev Pharmacoecon Outcomes Res; 2016 Aug; 16(4):483-8. PubMed ID: 27467881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pricing and reimbursement frameworks in Central Eastern Europe: a decision tool to support choices.
    Kolasa K; Kalo Z; Hornby E
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):145-55. PubMed ID: 24964864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.